New York City, NY, United States
New York City, NY, United States

Time filter

Source Type

Genetic factors significantly influence susceptibility for substance abuse and mood disorders. Rodent studies have begun to elucidate a role of Cav1.3 L-type Ca2+ channels in neuropsychiatric-related behaviors, such as addictive and depressive-like behaviors. Human studies have also linked the CACNA1D gene, which codes for the Cav1.3 protein, with bipolar disorder. However, the neurocircuitry and the molecular mechanisms underlying the role of Cav1.3 in neuropsychiatric phenotypes are not well established. In the present study, we directly manipulated Cav1.3 channels in Cav1.2 dihydropyridine insensitive mutant mice and found that ventral tegmental area (VTA) Cav1.3 channels mediate cocaine-related and depressive-like behavior through a common nucleus accumbens (NAc) shell calcium-permeable α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (CP-AMPAR) mechanism that requires GluA1 phosphorylation at S831. Selective activation of VTA Cav1.3 with (±)-BayK-8644 (BayK) enhanced cocaine conditioned place preference and cocaine psychomotor activity while inducing depressive-like behavior, an effect not observed in S831A phospho-mutant mice. Infusion of the CP-AMPAR-specific blocker Naspm into the NAc shell reversed the cocaine and depressive-like phenotypes. In addition, activation of VTA Cav1.3 channels resulted in social behavioral deficits. In contrast to the cocaine- and depression-related phenotypes, GluA1/A2 AMPARs in the NAc core mediated social deficits, independent of S831-GluA1 phosphorylation. Using a candidate gene analysis approach, we also identified single-nucleotide polymorphisms in the CACNA1D gene associated with cocaine dependence in human subjects. Together, our findings reveal novel, overlapping mechanisms through which VTA Cav1.3 mediates cocaine-related, depressive-like and social phenotypes, suggesting that Cav1.3 may serve as a target for the treatment of neuropsychiatric symptoms.Molecular Psychiatry advance online publication, 14 February 2017; doi:10.1038/mp.2017.9. © 2017 Macmillan Publishers Limited, part of Springer Nature.

"Nurses are at the center of delivering a quality, compassionate patient care experience. AMN Healthcare is honored to recognize the exceptional service of nurses throughout the world this week," said Susan Salka, AMN Healthcare President and CEO.  "We are also very proud that some of the finest nurses in the country have or are currently working with the AMN team providing outstanding care for our clients. Their commitment to their profession and their advocacy for patients and their families is inspiring to us all." Per diem and travel nurses have always been an essential part of any effective healthcare system and are becoming increasingly important as the healthcare industry faces a growing nurse shortage and increased need for workforce flexibility. Research confirms that per diem and travel nurses provide quality of care that is equivalent to their permanent counterparts. The following four outstanding AMN travel nurses were chosen by a committee of AMN clients, clinicians and recruiters. These nurses showed an unwavering commitment to excellence in the nursing profession that goes far beyond their job requirements. The nominations were a testament to the high quality of nurses that AMN Healthcare has on assignment. The Innovation Award went to Jennifer Ordonez, RN BSN, an ICU Nurse on assignment in Palm Springs, CA, for her ongoing pursuit of personal and professional excellence through innovation and the advancement of patient care. As her nomination stated, "Jennifer goes beyond the care and comfort of the patient to provide life-changing care. This is the definition of excellence." The Passion Award for exemplifying the highest standards of professional excellence through leadership and extraordinary commitment to service throughout their healthcare community went to Allison Griffin, RN, BLS, CHEMO, PALS, PMD, a Pediatric Nurse on assignment in Boston, MA. Allison was selected because she "is able to impact the lives of the children and their families with her care and compassion in a meaningful way each and every day!" The Customer Focus Award for demonstrating an unwavering dedication to the improvement of patient care across all specialties and embodying the core values of the nursing profession in actions and words went to Sandra Shrago, RN, ACLS, BSN, an ICU Nurse on assignment at NewYork-Presbyterian/ Columbia University Medical Center in New York, NY. Sandra was nominated for this award because she "encompasses all that nursing should represent, going above and beyond what is standard, setting a bar for herself, for her care of others. Her amiable demeanor, warm smile and linguistic adeptness proves to be a pleasure and an asset." The Overall Commitment to Excellence Award for all of these qualities, and continually striving to improve patient care through education and innovation, displaying an unmatched passion for the profession was given to Sonia Washington, RN, ACLS, BLS, PALS, an ICU Nurse on assignment at Hilo Medical Center in Hilo, HI. "Sonia's respect of patients, families, physicians, and quick adaption to local culture make her shine," said Sonia's supervisors at Hilo Medical Center. "Sonia demonstrated the professional conduct and compassion our ICU Beacon Status department is known for and expects. Sonia has an outgoing personality, participates in our teamwork philosophy… and works above and beyond as a patient advocate." NewYork-Presbyterian NewYork-Presbyterian is one of the nation's most comprehensive, integrated academic healthcare delivery systems, whose organizations are dedicated to providing the highest quality, most compassionate care and service to patients in the New York metropolitan area, nationally, and throughout the globe. In collaboration with two renowned medical schools, Weill Cornell Medicine and Columbia University Medical Center, NewYork-Presbyterian is consistently recognized as a leader in medical education, groundbreaking research and innovative, patient-centered clinical care. For more information, visit and on Facebook, Twitter and YouTube. Hilo Medical Center As the Big Island's leading provider of nationally recognized 4-star care, Hilo Medical Center (HMC) delivers a full range of services and programs. Our 20-acre campus consists of 276 beds located throughout the 137-bed acute hospital, 20-bed behavioral health unit and a 119-bed long-term care facility. We have over 1,000 employees and a medical staff comprised of 250 physicians, physician assistants and Advanced Practice Registered Nurses, representing 33 specialties. As a medical center, we have a network of nine outpatient clinics offering primary and specialty care. The hospital is a Level III Trauma Center which includes the second busiest emergency room in the state that provides 24-hour care to nearly 48,000 patients annually. In 2016, the Centers for Medicare & Medicaid Services (CMS) ranked HMC 4 stars for Overall Hospital Quality, putting our hospital in the top 20% in the nation, among the top 5 hospitals in the state, and named HMC the only 4-star hospital on Hawaii Island. Also in 2016, our Intensive Care Unit was designated as a bronze level for Beacon Award of Excellence – only the second ICU in the state to receive this designation. HMC received the 2016 American Heart Association Gold Plus Award for heart failure. HMC has also been recognized for quality long term care by Providigm for Quality Assurance & Performance Improvement Accredited Facility and Embracing Quality Award for the Prevention of Hospital Readmissions. Our long term care met the requirements for the American Health Care Association's Three Tier Level Quality Initiative Recognition Program. HMC ranks in the top 2% of hospitals in country and best in the state of Hawaii for preventing Hospital Acquired Conditions, according to CMS in 2015. The hospital is also a recipient of the 2015 Healthgrades Patient Safety Excellence Award™ and a past recipient of the Mountain Pacific Quality Health's Quality Achievement Award. HMC received the HIMSS Nicholas E. Davies Award for Excellence in 2015 for demonstrating EMR utilization to improve quality of care and financial management. We are part of the Hawaii Health Systems Corporation, a public entity established in 1996 by the State of Hawaii to fulfill the promise to provide quality, hometown healthcare. For more information, go to: About AMN Healthcare AMN Healthcare is the leader and innovator in healthcare workforce solutions and staffing services to healthcare facilities across the nation. The Company provides unparalleled access to the most comprehensive network of quality healthcare professionals through its innovative recruitment strategies and breadth of career opportunities. With insights and expertise, AMN Healthcare helps providers optimize their workforce to successfully reduce complexity, increase efficiency, and improve patient outcomes. AMN delivers managed services programs, healthcare executive search solutions, vendor management systems, recruitment process outsourcing, predictive modeling, medical coding and consulting, and other services. Clients include acute-care hospitals, community health centers and clinics, physician practice groups, retail and urgent care centers, home health facilities, and many other healthcare settings. For more information about AMN Healthcare, visit To view the original version on PR Newswire, visit:

NEW YORK, NY--(Marketwired - May 08, 2017) - Dr. Laura Forese, executive vice president and chief operating officer of NewYork-Presbyterian, has been named among the top 25 COOs in the country by Modern Healthcare. The inaugural list recognizes COOs from a broad spectrum of healthcare organizations who have made a transformative impact on their respective institutions. "NewYork-Presbyterian would not be where it is today if not for Dr. Forese's exceptional vision, work ethic and judgment," said Dr. Steven J. Corwin, president and CEO, NewYork-Presbyterian. "I am proud to work alongside her as we deliver world-class care to a growing number of patients." Modern Healthcare determined its list based on criteria including scope of duties, quality of patient care, staff satisfaction and the COO's ability to foster innovation and cross-departmental synergies. The list was created to recognize the increasingly important role COOs play in healthcare. Dr. Forese was named executive vice president and chief operating officer of NewYork-Presbyterian in 2015. She is responsible for achieving NewYork-Presbyterian's operating targets and implementing a patient-centered strategic vision and culture across the enterprise. Under her leadership, NewYork-Presbyterian has expanded its Regional Hospital Network, improved in several important patient experience metrics and launched groundbreaking digital health programs. NewYork-Presbyterian Hospital, a six-campus academic medical center, has been the top-ranked hospital in New York and among the best in the country according to U.S. News and World Report since she has been in her current position. Dr. Forese has been in leadership roles at NewYork-Presbyterian for more than a decade, starting as vice president of medical affairs in 2003. Since then, she has served as chief medical officer; group senior vice president and chief operating officer for NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian Westchester Division and NewYork-Presbyterian Lower Manhattan Hospital; and president of the former NewYork-Presbyterian Healthcare System. In addition to her work at NewYork-Presbyterian, she is the chairperson of the National Institutes of Health Clinical Center Hospital Board. NewYork-Presbyterian is one of the nation's most comprehensive, integrated academic healthcare delivery systems, whose organizations are dedicated to providing the highest quality, most compassionate care and service to patients in the New York metropolitan area, nationally, and throughout the globe. In collaboration with two renowned medical schools, Weill Cornell Medicine and Columbia University Medical Center, NewYork-Presbyterian is consistently recognized as a leader in medical education, groundbreaking research and innovative, patient-centered clinical care. For more information, visit and find us on Facebook, Twitter and YouTube.

Rogosin staff have already been working closely for more than a year with the Brooklyn Borough President's Office, community leadership, Brookdale University Hospital and Medical Center, Brownsville Multi-Service Family Center, and CAMBA, as well as faith-based, governmental, recreational, and other local leadership to form the Central Brooklyn Health Movement, the purpose of which is to encourage residents to take more responsibility for improving their own health.  Rogosin believes that this approach represents the future of the delivery of health care, and is committed to bringing that future to life now.  Brooklyn is where this can, and should, be happening. The new Linden Boulevard facility offers a 28-station, state-of-the-art kidney dialysis program provided by a staff of dedicated physicians, nurses, technicians, social workers and dietitians. Its Kidney Care and Education Center, working in collaboration and coordination with many other organizations, will provide residents with a community resource for health education and prevention programs, including risk factor identification, screening, nutrition counseling, transplant awareness programs and management of early chronic kidney disease.  Most importantly, the new Center will partner with the people themselves. "This new Center will combine the provision of the very best in kidney care, while focusing also on health promotion, disease prevention, and health education to make a real difference in both the health and quality of life of the people and community with whom we will be working.  We are privileged to be part of the East New York/Brownsville community and to be able to partner not only with the community but also the great organizations already serving the people here.  Together, we can make a great difference for health and life!" commented Barry Smith, President and CEO of Rogosin. "It is vital that Brooklynites have options to seek treatment and preventative information for kidney disease," said Brooklyn Borough President Eric L. Adams. "I applaud The Rogosin Institute for opening up their newest Dialysis and Kidney Care and Education Center in East New York. This facility will provide the local community and others in surrounding neighborhoods with early diagnostics, preventative care, and educational support that are so desperately needed in this part of Brooklyn. East New York is disproportionately affected by kidney disease, and I'm certain The Rogosin Institute will serve as a critical resource for many." The Rogosin Institute Dialysis and Kidney Care and Education Center is located at 2372 Linden Blvd, East New York, Brooklyn with a 13,500 sq. ft. dialysis center. The Center will be fully operational on or about May 22, 2017. About The Rogosin Institute Rogosin is an independent not-for-profit treatment and research center affiliated with NewYork-Presbyterian Hospital (NYPH) and Weill Cornell Medicine. It is a Sponsored Member of the NewYork-Presbyterian Regional Hospital Network. Rogosin is one of the nation's leading centers for kidney disease, providing services from early stage disease to more serious problems requiring dialysis and transplantation. The Institute is unique in its combination of the best in clinical care with research into new and better ways to prevent and treat kidney disease, as well as the diseases that contribute to it, such as hypertension, diabetes, and lipid disorders. The Rogosin Institute is committed to produce a unique applicable model for optimal, cost-effective health care and health promotion. To view the original version on PR Newswire, visit:

NEW YORK, NY--(Marketwired - May 10, 2017) - Dr. Peter M. Fleischut has been named senior vice president and chief transformation officer at NewYork-Presbyterian, effective May 1. In this new role, Dr. Fleischut will lead enterprise integration, transformation for clinical operations, innovation initiatives, logistics and pharmacy. He will also oversee the implementation of clinical technology operations for the new David H. Koch Center at NewYork-Presbyterian/Weill Cornell Medical Center, which is slated to open in 2018. "Dr. Fleischut has already led NewYork-Presbyterian to national prominence in telemedicine and patient-focused innovation," said Daniel Barchi, chief information officer at NewYork-Presbyterian. "As chief transformation officer, he will help drive integration and optimization of clinical processes across our entire enterprise." Most recently, Dr. Fleischut served as NewYork-Presbyterian's chief innovation officer, where he led the development of NYP OnDemand, NewYork-Presbyterian's comprehensive digital health program that offers a suite of services including Second Opinion, Urgent Care and Express Care. As chief transformation officer, he will maintain these responsibilities with the added focus of developing and instituting innovative solutions that are scaled across NewYork-Presbyterian's enterprise, developing governance structure for innovation, establishing cross-departmental collaborations and recruiting and mentoring innovative talent. "It's an honor to continue to revolutionize how we define and offer patient care," said Dr. Fleischut, an associate professor of anesthesiology at Weill Cornell Medicine. "I am excited to continue this work at such a wonderful institution." Dr. Fleischut joined NewYork-Presbyterian/Weill Cornell Medical Center in 2006 and has held many roles since then, including: medical director of the operating rooms, deputy quality patient safety officer, founding director of the Center for Perioperative Outcomes, chief medical information officer, chief medical operating officer and vice chairman of the Department of Anesthesiology at Weill Cornell Medicine. Dr. Fleischut retains his appointment as associate professor of anesthesiology at Weill Cornell Medicine. A graduate of Jefferson Medical College and the Wharton School at the University of Pennsylvania, Dr. Fleischut completed his residency training in anesthesiology at NewYork-Presbyterian/Weill Cornell Medical Center. He distinguished himself by becoming one of the founding members of the Housestaff Quality Council©, an organization formed to improve patient care and safety by creating a culture that promotes greater housestaff participation, and served as resident quality and patient safety officer for NewYork-Presbyterian. Dr. Fleischut has received numerous awards and honors, including NewYork-Presbyterian's Physician of the Year, the David A. Leach Award for Innovation in Quality from the Accreditation Council on Graduate Medical Education and the Weill Cornell Medical College (now Weill Cornell Medicine) Healthcare Leadership Award. In 2016 and 2017, he led NewYork-Presbyterian to CIO100 recognition, the InformationWeek Elite 100 and the President's Award from the American Telehealth Association for healthcare redesign for the release of NYP OnDemand. NewYork-Presbyterian is one of the nation's most comprehensive, integrated academic healthcare delivery systems, whose organizations are dedicated to providing the highest quality, most compassionate care and service to patients in the New York metropolitan area, nationally, and throughout the globe. In collaboration with two renowned medical schools, Weill Cornell Medicine and Columbia University Medical Center, NewYork-Presbyterian is consistently recognized as a leader in medical education, groundbreaking research and innovative, patient-centered clinical care. For more information, visit and find us on Facebook, Twitter and YouTube.

Specifically, providers should invest in the development of more robust risk-stratification tools that incorporate non-clinical risk factors, Dr. Weaver said. Historically, providers have not systematically evaluated how often and how deeply patients' health is affected by social barriers, such as transportation, housing, and environmental issues. The most successful provider organizations adopt the updated risk-stratification process and then develop unique care models to address the needs of the patients identified by the process. With better understanding of community health needs, health systems can secure their future success in the new care models by building more effective care network assets (such as new care sites and community partnerships) and care management teams, Dr. Weaver said. These teams, when deployed effectively, create structures to proactively help patients better manage their own health and avoid unnecessary hospitalizations. This impactful level of patient engagement often requires health systems to partner with community organizations to remove barriers to accessing holistic care. Fellow panelists at the WHCC session were moderator Jill Brown, Executive Editor at AISHealth; Paul N. Casale, MD, MPH, a cardiologist and Executive Director of NewYork Quality Care, the ACO of NewYork-Presbyterian, Weill Cornell Medicine, and Columbia University College of Physicians and Surgeons; and John Bulger, DO, Chief Medical Officer, Population Health at Geisinger Health System and Chief Medical Officer at Geisinger Health Plan. WHCC brought together more than 1,200 executives, experts, and administrators from Fortune 500 companies, insurers, hospitals, and pharmaceutical and biotech companies. About Advisory Board Advisory Board is a best practices firm that uses a combination of research, technology, and consulting to improve the performance of 4,500+ health care organizations. As the health care business of The Advisory Board Company (NASDAQ: ABCO), Advisory Board forges and finds the best new ideas and proven practices from its network of thousands of leaders, then customizes and hardwires them into every level of member organizations, creating enduring value. For more information, visit To view the original version on PR Newswire, visit:

Personal DNA sequencing once promised to up the ante for individualized medicine. Perhaps no one believed that more than human genomics pioneer J. Craig Venter, who in 2014 co-founded a company called Human Longevity to predict and prevent disease by sequencing a million human genomes. But Venter is no longer content with your DNA. His latest venture—a subsidiary called Health Nucleus based in San Diego, California—says it can detect undiagnosed health problems by combining DNA analyses with a $25,000 workup including a whole-body MRI scan, metabolomics screening, 2 weeks of constant heart monitoring, pedigree analysis, microbiome sequencing, and a glut of standard laboratory tests. Enthusiasts of “precision medicine” say this kind of screening—similar to the U.S. National Institutes of Health’s (NIH’s) Precision Medicine Initiative—is the way of the future. But many other clinicians and researchers are leery or even downright outraged by the program’s potential for over diagnosis and what they see as lack of evidence for its benefits. Late last week, Venter and co-workers quietly published a paper on the preprint server bioRxiv—which does not use peer review—that appears to present data from the new project. According to the study, screening detected “age-related chronic diseases requiring prompt (<30 days) medical attention” in 8 % of the 209 participants, and MRIs found early-stage cancer in 2%. However, Health Nucleus did not confirm that the data were from its $25,000 medical exam, although descriptions of the diagnostics were nearly identical. “It’s a classic Craig Venter study that pushes the envelope of what is considered reasonable,” says Olivier Elemento, associate director at the Institute for Computational Biomedicine at Weill Cornell Medicine in Ithaca, New York. Meanwhile, Venter has been making the media rounds to promote the screening. On Fox Business, he said the exam finds “something seriously wrong” in 40% of participants (though that claim is left unexplained). CBS News reports that Venter’s group can predict Alzheimer’s disease 20 years in advance by scanning the 20 regions of the brain. And STAT news reports that the exams detect tumors early enough that every participant with cancer so far has been able to treat it, even the notoriously unforgiving pancreatic cancer. A spokesperson for Human Longevity said they would not comment on the contents of the paper until it is published in a peer-reviewed journal. Critics aren’t buying it. “If I wanted to write a Swiftian parody illustrating the insanity of this extreme version of [precision medicine], I could not have written a better paper,” says Nigel Paneth, a pediatrician and epidemiologist from Michigan State University in East Lansing, who cites a litany of problems that could result from the study including psychological damage, high medical costs, unnecessary tests, and “the absence of the slightest shred of evidence that any benefit will accrue to anyone.” Eric Topol, director of Scripps Translational Science Institute in San Diego says this is “kind of the most extensive diagnostic evaluation of people that has ever been done,” but he takes issue with billing the study as a precision medicine screening. “Is this precise or is this promiscuous?” he asks. “That term ‘precision medicine screening’ is very difficult to accept unless you prove that you are actually helping people. That hypothesis is still unproven after this paper was published,” Topol says. “What if it helps one and harms 10?” He’s particularly concerned  about running tests on people without a sound rationale. “Don’t do a bunch of tests unless there is a good reason; otherwise you get a bunch of false positives.” The study included twice as many men as women, and participants ranged in age from 20 to 98, with an average age of 55. A whopping 78% had “evidence of age-related chronic disease or risk factors,” which for the majority translated to diabetes or risk of atherosclerotic disease. Michael Joyner, a medical doctor and integrative physiology researcher at the Mayo Clinic in Rochester, Minnesota, also notes that over 70% of the participants are currently taking prescribed medication for high LDL cholesterol and hypertension. “To tell me that a bunch of 60-year-old men with prolonged EKG monitoring had some funny heartbeats … is news, give me a break,” he says. “The whole thing is an example of technology run amok from a belief that if you can measure it, it must be meaningful.” But the amped up testing has its proponents. “The over-diagnosis concern is completely over-exaggerated,” says Michael Snyder, the director of the Stanford Center for Genomics and Personalized Medicine in Palo Alto, California, who made news 5 years ago when he detected his own diabetes by intensively studying his body. “Some of the stuff they found seems pretty serious, so I think it is a good thing to catch that early,” he says, predicting that in the future, “we will be measuring thousands of things much more routinely.” Despite Venter’s personalized genomics evangelism, the study’s results pointedly indicate that “the genome alone doesn’t tell you the whole story,” says Elemento of Cornell. Only 25% of patients had probable links between gene variants and disease phenotypes. “But when you can combine genes with an additional readout that tells you the gene is doing something, your ability to predict disease increases dramatically.” Some see the early data from Health Nucleus as the potential start of another Venter-versus-the government scenario. “What Venter has done here is pretty much the goal of NIH’s Precision Medicine Initiative, and I imagine Craig envisions immediate scale-up to compete with that particular government project,” says Robert W. West Jr., who previously taught a course on precision medicine at SUNY Upstate Medical University. “If this is really Craig’s goal, then he would likely beat NIH to the punch again.” Health Nucleus says 570 people have participated in the full $25,000 panoramic medical workups thus far, but this week they launched a $7500 pared-down version that focuses on the full genome sequencing and full-body scan. “This is a study that is going to remain controversial,” Topol says. “And maybe it is futuristic, but I think most people in medicine who understand the history of this will know that this is potentially engendering trouble and doing all sorts of tests that don’t have any basis.”

NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) today announced that Ronald O. Perelman and Dr. Anna Chapman, through the Perelman Family Foundation, have committed more than $4 million in funding to launch the first ever research program solely dedicated to the early detection and prevention of multiple myeloma. This generous donation will seed the launch of the groundbreaking Perelman Family Foundation Early Disease Translational Research Program, part of the MMRF Prevention Project, to speed efforts toward early detection, delayed disease progression, and eventually, ultimately, prevention of this incurable disease. “The goal of this initiative is to develop a completely new paradigm for research in multiple myeloma, focusing on early detection and ultimately, prevention. Right now, detection of this terrible disease often comes too late. Unlike most cancers, early detection of multiple myeloma doesn't increase a person’s chance of survival under current treatment options. The Perelman Family Foundation Early Disease Translational Research Program will support research focused on improving outcomes after early detection. With the MMRF and our university partners, we are confident that we will be able to make breakthroughs for multiple myeloma patients, and that the program will serve as a model for future initiatives,” said Dr. Anna Chapman. The gift from the Perelman Family Foundation provides a catalyst for essential research focused on: better understanding genomic determinants of early disease progression; how microenvironment factors influence early disease progression; and enhancing patient tumor immunity. Perelman Family Foundation Early Disease Translational Research Program brings together six leading cancer research centers: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Rockefeller University, University of Arkansas for Medical Science, Yale University, as well as the MMRF. The studies conducted by these teams will identify novel targets and biomarkers of disease progression and enable the development of therapeutic approaches to delay or even stop progression to myeloma. “We are so thankful to Ronald and Anna for supporting our vision for a bold program that will take us one step closer to a future where our children and grandchildren will never need to worry about incurable cancers,” said the Multiple Myeloma Research Foundation Founder Kathy Giusti. “Not only does the MMRF answer the questions of patients today and urgently deliver them the precise information and treatment they need to fight their multiple myeloma, but, with this generous donation, we will now also be able to focus on the patients of tomorrow.” Inspired by the dedication and vision of its Chairman and CEO Ronald O. Perelman and his family, the Perelman Family Foundation is firmly committed to philanthropy, focusing on women’s health, education and the arts. Ranked among the top philanthropists in the United States, Mr. Perelman is the founder of the Revlon/UCLA Women’s Cancer Research Program, which analyzes the causes of and develops groundbreaking treatment for breast and ovarian cancer. Launched in 1994, the program was responsible for the development of Herceptin, the first genetically-based treatment for a major cancer to be approved by the FDA, which currently cures more than thirty percent of breast cancer cases in women. In 2014, he co-founded, along with Barbra Streisand, the Women’s Heart Alliance to raise awareness, encourage action and drive new research to fight heart disease in women. Through the Perelman Family Foundation, Mr. Perelman supports the Ronald O. Perelman Center for Emergency Services and the Ronald O. Perelman Department of Dermatology at NYU Langone Medical Center; the Ronald O. Perelman Heart Institute at New York Presbyterian Hospital, an internationally-recognized center offering comprehensive, innovative, and world-class cardiovascular care and heart health education; and the Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine at Weill Cornell Medicine. Multiple myeloma is a cancer of the plasma cell. It is the second most common blood cancer. An estimated 30,280 adults will be diagnosed this year and 12,590 people are predicted to die from the disease. The mission of the Multiple Myeloma Research Foundation (MMRF) is to find a cure for multiple myeloma by relentless pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501 (c) (3) nonprofit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF has created the only end-to-end solution in precision medicine and the single largest genomic dataset in all cancers. The MMRF continues to disrupt the industry today, as a pioneer and leader at the helm of new research efforts. Since its inception, the organization has raised over $350 million and directs nearly 90% of the total funds to research and related programs. As a result, the MMRF has been awarded by Charity Navigator’s coveted four-star rating for 12 years, the highest designation for outstanding fiscal responsibility and exceptional efficiency.

Loading Weill Cornell Medicine collaborators
Loading Weill Cornell Medicine collaborators